Interleukin-2 is an increasingly important immune system cytokine with growing implications for immunotherapy research and practice. Recent studies suggest that IL-2 has a strong effect on promoting survival and function of regulatory T cells, which are in turn responsible for suppressing the responsiveness of natural killer (NK) cells (Leavy; Nature Rev Immunology 2013; Gastgeier et al.; JEM 2013). Moreover, this is particularly significant for patients infected with hepatitis C, who are known to have reduced levels of regulatory T cells (Saadoun et al., New England Journal of Medicine 2011).
Moreover, uses of interleukin-2 for immunotherapy extends into melanoma treatment. While early diagnosis is beneficial, treating disseminated melanoma is still a serious challenge. One of the treatments that has shown to be clinically beneficial in treating patients with stage IV melanoma includes immunotherapy with high-dose interleukin-2 (IL-2). The National Cancer Institute reports that response to high-dose IL-2 treatments generally ranges from 10% to 20% [Atkins et al, J Clin Oncol 1999]. The antitumor activity of IL-2 is the subject of an increasing number of scientific studies [Yao et al., Mol Cancer Ther 2011] as attempts to improve on this therapy are being evaluated.
Akron Biotech offers cGMP, high grade and research grade Interleukin-2 to support immunotherapy research. For custom requirements such as cGMP, we would be happy to tailor the product to meet your needs. Contact us.